Data Insights

NKT-3447 by NiKang Therapeutics for Gastric Cancer: Likelihood of Approval

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - NKT-3447 in Gastric Cancer

Data Insights

NKT-3447 by NiKang Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - NKT-3447 in Small-Cell Lung Cancer

Data Insights

NKT-3447 by NiKang Therapeutics for Solid Tumor: Likelihood of Approval

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - NKT-3447 in Solid Tumor

Data Insights

NKT-3447 by NiKang Therapeutics for Endometrial Cancer: Likelihood of Approval

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - NKT-3447 in Endometrial Cancer

Data Insights

NKT-3447 by NiKang Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - NKT-3447 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

NKT-3447 by NiKang Therapeutics for Metastatic Ovarian Cancer: Likelihood of Approval

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - NKT-3447 in Metastatic Ovarian Cancer

Data Insights

NKT-3447 by NiKang Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - NKT-3447 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

NKT-3447 by NiKang Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - NKT-3447 in Triple-Negative Breast Cancer (TNBC)